AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29356271 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative serum (Matricium®)
Number of subjects: 0
Study 26807488 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line platinum/taxane combination chemotherapy
Number of subjects: 145
Study 26807488 — intervention group
Group type: COMPARATOR
Intervention: Control cohort of high-grade serous ovarian cancer (HGSOC)
Number of subjects: 145
Study 26807488 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cytoreduction
Number of subjects: 145
Study 24136153 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 15 mg bid
Number of subjects: 0
Study 24136153 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg qd
Number of subjects: 0
Study 24136153 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg bid
Number of subjects: 0
Study 24136153 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 60 mg qd
Number of subjects: 0
Study 24136153 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg qd
Number of subjects: 0
Study 22917830 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted apical suction (VAS)
Number of subjects: 20
Study 22917830 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep pericardial traction suture (DPTS)
Number of subjects: 20
Study 21083385 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-770 150 mg
Number of subjects: 39
Study 18765400 — intervention group
Group type: EXPERIMENTAL
Intervention: CS‐10 prepared spermatozoa
Number of subjects: 28
Study 18765400 — intervention group
Group type: COMPARATOR
Intervention: DGC prepared spermatozoa
Number of subjects: 28
Study 16404415 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol group (2 g/day)
Number of subjects: 164
Study 16404415 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study 14974339 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioguard coronary filter
Number of subjects: 31
Study 14974339 — intervention group
Group type: COMPARATOR
Intervention: Control group without protection device
Number of subjects: 31
Study 10862204 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with patch closure (CEAP)
Number of subjects: 86
Study 10862204 — intervention group
Group type: COMPARATOR
Intervention: Carotid eversion endarterectomy (CEE)
Number of subjects: 86
Study 9174684 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (150 ml)
Number of subjects: 12
Study 9174684 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 1540759 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168
Study 1540759 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168
Study 1540759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1168
Study 4076364 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 puffs of 50 micrograms BDP twice daily (AM/PM)
Number of subjects: 23
Study 4076364 — intervention group
Group type: COMPARATOR
Intervention: 8 puffs of 50 micrograms BDP once daily (AM)
Number of subjects: 23
Study 29915962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin nasal spray
Number of subjects: 100
Study 29915962 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 100
Study 26465232 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite sublingual immunotherapy (HDM AIT)
Number of subjects: 484
Study 26465232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study 24780180 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Number of subjects: 115
Study 24780180 — intervention group
Group type: COMPARATOR
Intervention: Support group
Number of subjects: 115
Study 23078375 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3 supplementation
Number of subjects: 0
Study 23078375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic)
Number of subjects: 0
Study 20883231 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent patients
Number of subjects: 434
Study 20883231 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent individuals
Number of subjects: 434
Study 18691854 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 150 IU/kg
Number of subjects: 313
Study 18691854 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta 300 IU/kg
Number of subjects: 313
Study 18691854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 18691854 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous Epoetin delta 150 IU/kg
Number of subjects: 313
Study 18691854 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous Epoetin delta 300 IU/kg
Number of subjects: 313
Study 18691854 — intervention group
Group type: COMPARATOR
Intervention: Previous Placebo
Number of subjects: 313
Study 15977099 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg cerivastatin
Number of subjects: 103
Study 15977099 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg cerivastatin
Number of subjects: 103
Study 15977099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 14654482 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolytic therapy with various plasminogen activators
Number of subjects: 0
Study 14654482 — intervention group
Group type: COMPARATOR
Intervention: Existing large clinical trials in acute myocardial infarction
Number of subjects: 0
Study 10354297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) 300 mg three times per week for eight weeks
Number of subjects: 65
Study 10354297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVAA treatment)
Number of subjects: 65
Study 7589016 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Lisinopril
Number of subjects: 22
Study 7589016 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Bisoprolol
Number of subjects: 22
Study 2013204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 200 mg b.i.d.
Number of subjects: 545
Study 2013204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 300 mg b.i.d.
Number of subjects: 545
Study 2013204 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 500 mg t.i.d.
Number of subjects: 545
Study 6802657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin (32 g daily, 25% phosphatidylcholine)
Number of subjects: 16
Study 6802657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (powdered skim milk equivalent)
Number of subjects: 16
Study 31670874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 9298
Study 31670874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment
Number of subjects: 9298
Study 31670874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 9298
Study 30156450 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 186132
Study 30156450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 186132
Study 30156450 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 186132
Study 30156450 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 186132
Study 27007077 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI) training
Number of subjects: 20
Study 27007077 — intervention group
Group type: COMPARATOR
Intervention: Low-Fidelity (LF) simulation training
Number of subjects: 20
Study 25055558 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment (50 IU monthly for 6 months)
Number of subjects: 94
Study 25055558 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 94
Study 25055558 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment of CHF
Number of subjects: 94
Study 22265113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory-random student drug testing (MRSDT) implemented immediately in treatment schools
Number of subjects: 4700
Study 22265113 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed MRSDT implementation)
Number of subjects: 4700
Study 22265113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory-random student drug testing (MRSDT)
Number of subjects: 4700
Study 19124037 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic contours with dots moving in one of two regions (Experiment 1)
Number of subjects: 0
Study 19124037 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic contours with dots moving in both the figure and the background (Experiment 2)
Number of subjects: 0
Study 17963300 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-interferon alpha-2b treatment
Number of subjects: 49
Study 15040823 — intervention group
Group type: EXPERIMENTAL
Intervention: Active devices (0.3g, 90 Hz) for 10 minutes/day, 5 days/week for 6 months
Number of subjects: 20
Study 15040823 — intervention group
Group type: COMPARATOR
Intervention: Placebo devices for 10 minutes/day, 5 days/week for 6 months
Number of subjects: 20
Study 12428178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessment
Number of subjects: 12124
Study 12428178 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting assessment
Number of subjects: 12124
Study 12428178 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight assessment
Number of subjects: 12124
Study 12428178 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient intake assessment
Number of subjects: 12124
Study 12428178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment
Number of subjects: 12124
Study 9559842 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal microwave hyperthermia (TMH) therapy
Number of subjects: 80
Study 9559842 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 80
Study 7650439 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil 600 mg/day for 14 days
Number of subjects: 398
Study 7650439 — intervention group
Group type: COMPARATOR
Intervention: Placebo 600 mg/day for 14 days
Number of subjects: 398
Study 7650439 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil and Placebo
Number of subjects: 398
Study 2664884 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine 16 mg
Number of subjects: 12
Study 2664884 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine 32 mg
Number of subjects: 12
Study 2664884 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 322570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (60 mg tablet)
Number of subjects: 0
Study 322570 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine nasal spray (positive control)
Number of subjects: 0
Study 30913216 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker managed mobile health intervention including household CVD risk assessments, electronic referral, clinical decision support, and follow-up tracking system.
Number of subjects: 62254
Study 30913216 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker managed mobile health intervention.
Number of subjects: 62254
Study 30913216 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention).
Number of subjects: 62254
Study 28460195 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules (PRO)
Number of subjects: 32
Study 28460195 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic + glutamine powder (PGLn)
Number of subjects: 32
Study 28460195 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (CON)
Number of subjects: 32
Study 25458558 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (0.9 mg/m²) in combination with pemetrexed (500 mg/m²) on day 1 of a 21-day cycle (E+P)
Number of subjects: 95
Study 25458558 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed alone (P)
Number of subjects: 95
Study 25458558 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate in combination with pemetrexed (E+P)
Number of subjects: 95
Study 23954381 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 booster
Number of subjects: 0
Study 23954381 — intervention group
Group type: COMPARATOR
Intervention: PPV booster
Number of subjects: 0
Study 23954381 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 and PPV
Number of subjects: 0
Study 21865334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 g n-3 LC-PUFAs/d
Number of subjects: 367
Study 21865334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g n-3 LC-PUFAs/d
Number of subjects: 367
Study 21865334 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g n-3 LC-PUFAs/d
Number of subjects: 367
Study 21865334 — intervention group
Group type: COMPARATOR
Intervention: Placebo (refined olive oil)
Number of subjects: 367
Study 19217086 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary task (responding to a moving dot) added to the AB task
Number of subjects: 0
Study 19217086 — intervention group
Group type: EXPERIMENTAL
Intervention: Control for learning and variation of rotating the first target
Number of subjects: 0
Study 17283559 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium/xylometazoline 1.0 mg/mL
Number of subjects: 786
Study 17283559 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium/xylometazoline 0.5 mg/mL
Number of subjects: 786
Study 17283559 — intervention group
Group type: COMPARATOR
Intervention: xylometazoline 1.0 mg/mL
Number of subjects: 786
Study 17283559 — intervention group
Group type: COMPARATOR
Intervention: ipratropium 0.6 mg/mL
Number of subjects: 786
Study 17283559 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 786
Study 15522021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured autologous melanocytes plus PUVA therapy (CMP)
Number of subjects: 20
Study 15522021 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blister transplantation plus PUVA therapy (SBP)
Number of subjects: 20
Study 15522021 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy plus PUVA therapy (CP)
Number of subjects: 20
Study 15522021 — intervention group
Group type: COMPARATOR
Intervention: Only PUVA therapy (OP)
Number of subjects: 20
Study 11454267 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention plus individual counsel
Number of subjects: 115
Study 11454267 — intervention group
Group type: COMPARATOR
Intervention: Individual counsel alone
Number of subjects: 115
Study 9492090 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (40 mg/kg/day in 2 divided doses for 2 months)
Number of subjects: 76
Study 9492090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 9492090 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 76
Study 9492090 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam and Placebo
Number of subjects: 76
Study 7529507 — intervention group
Group type: EXPERIMENTAL
Intervention: Proviral DNA level in PBMC
Number of subjects: 62
Study 7529507 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral RNA level in plasma
Number of subjects: 62
Study 7529507 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of p24 antigen in serum
Number of subjects: 62
Study 7529507 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SI strains
Number of subjects: 62
Study 7529507 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between proviral DNA and viral RNA levels
Number of subjects: 62
Study 7529507 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2M and neopterin concentrations in serum
Number of subjects: 62
Study 3336553 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising group
Number of subjects: 0
Study 3336553 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 0
Study 29409327 — intervention group
Group type: EXPERIMENTAL
Intervention: EQUIP intervention (4 face-to-face educational sessions with a nurse)
Number of subjects: 69
Study 29409327 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care (control group)
Number of subjects: 69
Study 27464024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral compound glycyrrhizin (OCG)
Number of subjects: 144
Study 27464024 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB applications twice weekly
Number of subjects: 144
Study 27464024 — intervention group
Group type: EXPERIMENTAL
Intervention: OCG+UVB
Number of subjects: 144
Study 24962611 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who encoded scenes in the evening, slept overnight, and took a recognition test the next morning
Number of subjects: 0
Study 24962611 — intervention group
Group type: COMPARATOR
Intervention: Participants who encoded scenes in the morning and remained awake during a comparably long retention interval
Number of subjects: 0
Study 24962611 — intervention group
Group type: COMPARATOR
Intervention: Control groups tested after a 20 min delay in the morning or evening
Number of subjects: 0
Study 22463890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone, 0.1 mg/kg twice daily for 12 months
Number of subjects: 222
Study 22463890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone with exercise program
Number of subjects: 222
Study 22463890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 20727144 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome subjects
Number of subjects: 40
Study 20727144 — intervention group
Group type: COMPARATOR
Intervention: Physically active controls
Number of subjects: 40
Study 18055130 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) variables including attitudes, norms, perceived behavioral control, and intentions
Number of subjects: 247
Study 16909273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate (600 mg)
Number of subjects: 24
Study 16909273 — intervention group
Group type: COMPARATOR
Intervention: Dexibuprofen (400 mg)
Number of subjects: 24
Study 12677281 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional hospitals
Number of subjects: 4605
Study 11508399 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrrh (12 mg/kg per day for 6 consecutive days)
Number of subjects: 7
Study 9431480 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 90
Study 9431480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 90
Study 9431480 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 90
Study 9431480 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 90
Study 9431480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 90
Study 9431480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8221370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 147
Study 3689630 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol hydrobromide (360 micrograms)
Number of subjects: 47
Study 3689630 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide (72 micrograms)
Number of subjects: 47
Study 3689630 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol sulphate (4 mg)
Number of subjects: 47
Study 3689630 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pirenzepine hydrochloride (50 mg)
Number of subjects: 47
Study 3689630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3689630 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilation (measured by sGaw and FEV1)
Number of subjects: 47
Study 29506674 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 223
Study 29506674 — intervention group
Group type: COMPARATOR
Intervention: Sham RIPC (Control)
Number of subjects: 223
Study 27160142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Alpha Lipoic Acid (10 mg)
Number of subjects: 62
Study 27160142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Progesterone (400 mg)
Number of subjects: 62
Study 27160142 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 62
Study 26201003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise (10-min bouts, 30 min per day, three days a week for 10 weeks)
Number of subjects: 30
Study 26201003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise
Number of subjects: 30
Study 23551886 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate (TU) 1,000 mg
Number of subjects: 199
Study 23551886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 20921111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Court (MHC)
Number of subjects: 1047
Study 20921111 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 1047
Study 18391342 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic guidance during laparoscopic simulation
Number of subjects: 0
Study 18391342 — intervention group
Group type: COMPARATOR
Intervention: No haptic guidance during laparoscopic simulation
Number of subjects: 0
Study 16858076 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography-mass spectrometry method
Number of subjects: 1
Study 14627851 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-HMPAO lung scans
Number of subjects: 21
Study 14627851 — intervention group
Group type: EXPERIMENTAL
Intervention: 67Ga citrate lung scans
Number of subjects: 21
Study 14627851 — intervention group
Group type: COMPARATOR
Intervention: Comparison between two groups of patients (normal chest X-ray findings vs abnormal X-ray findings)
Number of subjects: 21
Study 14627851 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis between L/L ratio and GUI
Number of subjects: 21
Study 10740355 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoking curriculum (8 lessons over 4 weeks)
Number of subjects: 1956
Study 9384462 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) at 75 mg m(‐2)
Number of subjects: 38
Study 9384462 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP)
Number of subjects: 38